Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Sells Shares Under 10b5-1 Plan

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock at an average price of $10.7695, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• On September 3, 2024, Howard G. Welgus, a director of Arcutis Biotherapeutics, sold 10,000 shares of common stock.
• The sale was executed under a 10b5-1 trading plan.
• The shares were sold at a weighted average price of $10.7695, with individual sales ranging from $10.67 to $10.865.
• Following the transaction, Welgus directly owns 191,944 shares.
• The reported total includes shares held in a revocable living trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook on the company's future.

Industry Context

Sales by company insiders are routinely monitored by investors. Sales under a 10b5-1 plan are generally viewed as less impactful than discretionary sales, as they are pre-arranged.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the 10b5-1 plan mitigates this concern.

Key Dates